Today, the Demo Day of the second edition of the Incibe Emprende startup acceleration program took place in Valencia. Ten startups presented their projects, and Evolving Therapeutics was selected as the winner in the acceleration category. Muvatech secured second place, and Banshee came in third.
Evolving Therapeutics, originating from the University of Valencia, focuses on developing personalized phage-based therapies to combat multi-resistant bacteria. Its goal is to improve human, animal, and environmental health, addressing a critical global health issue.
“"This acceleration program has helped ten startups and their founders make the best decisions, grow, and consolidate their sales in a secure digital environment."
The event, organized by the European Centre for Companies and Innovation of Valencia (CEEI Valencia), brought together professionals and representatives from the business sector. The day began with the presentation of the ten selected projects to a jury composed of Ramón Ferrandis (CEEI Valencia), Rocío Gutiérrez (Incibe), Luz Martínez (Zubi Group), and Jordi Oliver (S2 Grupo).
The Incibe Emprende program, funded by the Next Generation-EU Funds within the framework of the Recovery, Transformation and Resilience Plan, aims to strengthen the Valencian business ecosystem by promoting the creation of cyber-secure businesses. The involved entities seek to support innovative business ideas and startups with technological solutions that integrate cybersecurity.
During this edition, the selected teams received specialized training, personalized mentoring, legal and tax advice, and meetings with investors. The six-month program, comprising 15 sessions, has been extended until April 2026 and includes a 5,000 euro prize.
